Antigenic Site-Specific Competitive Antibody Responses to the Fusion Protein of Respiratory Syncytial Virus Were Associated With Viral Clearance in Hematopoietic Cell Transplantation Adults

被引:19
作者
Ye, Xunyan [1 ]
Iwuchukwu, Obinna P. [1 ]
Avadhanula, Vasanthi [1 ]
Aideyan, Letisha O. [1 ]
McBride, Trevor J. [1 ]
Ferlic-Stark, Laura L. [1 ]
Patel, Kirtida D. [1 ]
Piedra, Felipe-Andres [1 ]
Shah, Dimpy P. [2 ]
Chemaly, Roy F. [3 ,4 ,5 ]
Piedra, Pedro A. [1 ,6 ]
机构
[1] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX USA
[2] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Infect Dis, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Infect Control, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Employee Hlth, Houston, TX 77030 USA
[6] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA
关键词
competitive antibody; fusion protein; viral clearance; respiratory syncytial virus; hematopoietic cell transplantation; NEUTRALIZING ANTIBODIES; PEDIATRIC-PATIENTS; INFECTION; RSV; INFANTS; CHILDREN; VACCINE; MICE; REINFECTION; PATHOLOGY;
D O I
10.3389/fimmu.2019.00706
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Recent studies of human sera showed that the majority of the respiratory syncytial virus (RSV) neutralizing antibodies are directed against pre-fusion conformation of the fusion (F) protein of RSV and revealed the importance of pre-fusion antigenic site empty set specific antibodies. However, detailed analysis of multiple antigenic site-specific competitive antibody responses to RSV F protein and their contribution to virus clearance in humans are lacking. Methods: We prospectively enrolled a cohort of RSV infected hematopoietic cell transplantation (HCT) adults (n = 40). Serum samples were collected at enrollment (acute, n = 40) and 14 to 60 days post-enrollment (convalescent, n = 40). Antigenic site-specific F protein antibodies were measured against pre-fusion site empty set, post-fusion site I, and sites II and IV present in both the pre-fusion and post-fusion F protein conformations utilizing four different competitive antibody assays developed with biotinylated monoclonal antibodies (mAb) D25, 131-2A, palivizumab, and 101F, respectively. The lower limit of detection were 7.8 and 1.0 mu g/mL for the competitive antibody assays that measured site empty set specific response, as well as sites I, II, and IV specific responses, respectively. Neutralizing antibody titers to RSV A and B subgroups was determined by microneutralization assays. Results: The overall findings in RSV infected HCT adults revealed: (1) a significant increase in antigenic site-specific competitive antibodies in convalescent sera except for site empty set competitive antibody (p < 0.01); (2) comparable concentrations in the acute and convalescent serum samples of antigenic site-specific competitive antibodies between RSV/A and RSV/B infected HCT adults (p > 0.05); (3) significantly increased concentrations of the antigenic site-specific competitive antibodies in HCT adults who had genomic RSV detected in the upper respiratory tract for <14 days compared to those for >= 14 days (p < 0.01); and (4) statistically significant correlation between the antigenic site-specific competitive antibody concentrations and neutralizing antibody titers against RSV/A and RSV/B (r ranged from 0.33 to 0.83 for acute sera, and 0.50-0.88 for convalescent sera; p < 0.05). Conclusions: In RSV infected HCT adults, antigenic site-specific antibody responses were induced against multiple antigenic sites found in both the pre-fusion and post-fusion F conformations, and were associated with a more rapid viral clearance and neutralizing antibody activity. However, the association is not necessarily the cause and the consequence.
引用
收藏
页数:10
相关论文
共 41 条
[1]   Respiratory Syncytial Virus Infection Outbreak Among Pediatric Patients With Oncologic Diseases and/or BMT [J].
Anak, Sema ;
Atay, Didem ;
Unuvar, Aysegul ;
Garipardic, Mesut ;
Agaoglu, Leyla ;
Ozturk, Gulyuz ;
Karakas, Zeynep ;
Devecioglu, Omer .
PEDIATRIC PULMONOLOGY, 2010, 45 (03) :307-311
[2]   ANALYSIS OF THE LOCAL AND SYSTEMIC IMMUNE-RESPONSES INDUCED IN BALB/C MICE BY EXPERIMENTAL RESPIRATORY SYNCYTIAL VIRUS-INFECTION [J].
ANDERSON, JJ ;
NORDEN, J ;
SAUNDERS, D ;
TOMS, GL ;
SCOTT, R .
JOURNAL OF GENERAL VIROLOGY, 1990, 71 :1561-1570
[3]   Risk Factors and Outcomes for Respiratory Syncytial Virus-related Infections in Immunocompromised Children [J].
Asner, Sandra ;
Stephens, Derek ;
Pedulla, Paul ;
Richardson, Susan E. ;
Robinson, Joan ;
Allen, Upton .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2013, 32 (10) :1073-1076
[4]   Infection With Novel Respiratory Syncytial Virus Genotype Ontario (ON1) in Adult Hematopoietic Cell Transplant Recipients, Texas, 2011-2013 [J].
Avadhanula, Vasanthi ;
Chemaly, Roy F. ;
Shah, Dimpy P. ;
Ghantoji, Shashank S. ;
Azzi, Jacques M. ;
Aideyan, Letisha O. ;
Mei, Minghua ;
Piedra, Pedro A. .
JOURNAL OF INFECTIOUS DISEASES, 2015, 211 (04) :582-589
[5]   CYTO-TOXIC T-CELL RESPONSE TO RESPIRATORY SYNCYTIAL VIRUS IN MICE [J].
BANGHAM, CRM ;
CANNON, MJ ;
KARZON, DT ;
ASKONAS, BA .
JOURNAL OF VIROLOGY, 1985, 56 (01) :55-59
[6]   CYTO-TOXIC T-CELLS CLEAR VIRUS BUT AUGMENT LUNG PATHOLOGY IN MICE INFECTED WITH RESPIRATORY SYNCYTIAL VIRUS [J].
CANNON, MJ ;
OPENSHAW, PJM ;
ASKONAS, BA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1988, 168 (03) :1163-1168
[7]   DEVELOPMENT OF CELL-MEDIATED CYTO-TOXIC IMMUNITY TO RESPIRATORY SYNCYTIAL VIRUS IN HUMAN INFANTS FOLLOWING NATURALLY ACQUIRED INFECTION [J].
CHIBA, Y ;
HIGASHIDATE, Y ;
SUGA, K ;
HONJO, K ;
TSUTSUMI, H ;
OGRA, PL .
JOURNAL OF MEDICAL VIROLOGY, 1989, 28 (03) :133-139
[8]   Respiratory Viral Infections after Hematopoietic Stem Cell Transplantation in Children [J].
Choi, Jae Hong ;
Choi, Eun Hwa ;
Kang, Hyoung Jin ;
Park, Kyung Duk ;
Park, Sung Sup ;
Shin, Hee Young ;
Lee, Hoan Jong ;
Ahn, Hyo Seop .
JOURNAL OF KOREAN MEDICAL SCIENCE, 2013, 28 (01) :36-41
[9]  
Connor AL, 2001, J MED VIROL, V63, P168, DOI 10.1002/1096-9071(20000201)63:2<168::AID-JMV1012>3.0.CO
[10]  
2-U